JATT ACQUISITION CORP |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.75 USD | +7.71% |
|
+33.23% | -41.91% |
| 2023 | JATT Acquisition Corp Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
| 2023 | Zura Bio Completes Business Combination With JATT Acquisition | MT |
| Sales 2021 | - | Sales 2022 | - | Capitalization | 176M 14.05B |
|---|---|---|---|---|---|
| Net income 2021 | 8M 638M | Net income 2022 | 3M 239M | EV / Sales 2021 | - |
| Net cash position 2021 | 729K 58.17M | Net Debt 2022 | 342K 27.27M | EV / Sales 2022 | - |
| P/E ratio 2021 * |
-
| P/E ratio 2022 |
49.6
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 59.06% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.36% | ||
| Current month | -45.40% | ||
| Current year | -45.40% |
3 years
4.29
12.38
5 years
4.2912.38
10 years
4.2912.38
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 4.75 | +7.71% | 135 788 |
| 26/04/24 | 4.41 | +21.82% | 897,979 |
| 25/04/24 | 3.62 | +9.37% | 338,797 |
| 24/04/24 | 3.31 | -4.89% | 849,725 |
| 23/04/24 | 3.48 | +5.14% | 133,183 |
Delayed Quote Nyse, April 29, 2024 at 03:46 pm
More quotes
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs. Tibulizumab (ZB-106) is an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of TALTZ (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain (IL-7R) alpha. Torudokimab (ZB-880) is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
Sector
Investment Holding Companies
| 1st Jan change | Capi. | |
|---|---|---|
| -45.40% | 70.09M | |
| +157.71% | 5.68B | |
| +1.70% | 1.01B | |
| +2.19% | 982M | |
| +41.91% | 872M | |
| +26.00% | 819M | |
| +1.76% | 663M | |
| +1.80% | 610M | |
| -.--% | 600M | |
| +22.54% | 552M |
- Stock Market
- Equities
- JATT Stock
